Active Clinical Trials
Our Division has numerous clinical trials underway on type 1 and type 2 diabetes. For active clinical trials, click here.
We are also currently enrolling for a human growth hormone study (see Versartis Study below).
For more information on these clinical trials, contact Marla B. Hashiguchi, R.N., Research Coordinator, at 858-966-8940 or email@example.com.
Versartis Study (Human Growth Hormone)
The standard treatment for growth hormone deficiency is daily injections of human growth hormone. The purpose of this study is to see how well a longer-acting growth hormone will work in children.
The new growth hormone is called VRS-317. VRS-317 is made of natural human growth hormone but it has been modified to make its effects last longer. Animal studies showed that VRS-317 may be able to reduce the overall dose and number of injections per month. A clinical study in adult humans with growth hormone deficiency shows the same result. This study hopes to prove that growth hormone therapy with VRS-317 may require only 1 or 2 injections per month instead of every day injections.
The subjects will receive subcutaneous (under the skin) injections of VRS-317. This is the first time VRS-317 will be given to children.
There are two parts to the VRS-317 study. Each part has its own purpose. In Part 1, a single VRS-317 injection is given under the skin. The purpose of Part 1 is to see how safe and tolerable VRS-317 is when given to children. In addition, we will look at how long the injected VRS-317 stays in the body and how long it can stimulate the appearance of IGF-1. IGF-1 is a substance normally made in the body. IGF-1 is essential for normal growth in children. Starting with a low dose of VRS-317 for the first patient entering the study, the dose will be increased by studying additional children at higher doses. This is called an ascending dose study. Part 1, the ascending dose study, is over when the sponsor has identified what doses safely give the IGF-1 response that should lead to better growth in children.
The purpose of Part 2 is to see how well VRS-317 will help children with growth hormone deficiency to grow better. During Part 2, each participant will receive VRS-317 injections under the skin once or twice each month for six months.
Ages Eligible for Study: Chronological Age ≥ 3.0 years and ≤ 10.0 (girls) and ≤ 11.0 (boys)
Genders Eligible for Study: Both
- Division of Endocrinology/Diabetes
Rose Pavilion, First Floor (South)
3020 Children's Way
San Diego, CA 92123
- Phone: 858-966-4032
Referral Fax: 858-966-4051
- Click here for all locations.
- Monday-Friday, 8 a.m.- 4:30 p.m.: 858-966-4032
- After hours, weekends, holidays: 858-576-1700; press zero, then ask for the endocrine doctor on call.